Berenberg keeps Sobi at 'buy' on Altuvoct potential, sees sales guidance hike likely

Swedish Orphan Biovitrum AB (publ)

23/06/2026 12:43

** Berenberg keeps a bullish stance on Swedish Orphan Biovitrum (Sobi) SOBIV.ST, seeing the Swedish pharmaceutical company’s haemophilia A therapy Altuvoct as primary upside driver in the near term 
** It repeats its "buy" rating and raises target price by 5% to SEK 550 ($56.74)
** Berenberg’s 2026-29 Sobi revenue and operating profit forecasts are 3-7% and 5-11% ahead of consensus, respectively, supported by what the broker calls its bullish Altuvoct outlook
** Following new expert calls, the brokerage estimates Altuvoct sales to reach SEK 6.6 billion in 2026 versus consensus of SEK 5.5 billion
** "We expect Sobi to raise its 2026 revenue growth guidance in constant currency from a low-double-digit percentage to a mid-teens percentage at its Q2 2026 results," it adds
** Berenberg’s higher sales and earnings forecasts for Sobi are also partly supported by lower foreign exchange headwinds, primarily due to USD/SEK appreciation
** Sobi's shares are up about 3%, making it one of the top performers on the European STOXX 600 index .STOXX
** The stock is on track for best day since April 2026
** Out of 13 analysts that cover Sobi, 10 rate the stock "buy" or "strong buy," and three rate it ''hold'' - LSEG data
($1 = 9.6925 Swedish crowns)

(Reporting by Alexander Klyve Gudbrandsen)
((alexanderklyve.gudbrandsen@thomsonreuters.com))